

4.12. Inhibitors of Bruton's tyrosine kinase (BTK)	433
4.13. Inhibitors of tropomyosin receptor kinase (Trk)	434
5. Inhibitors of serine–threonine kinases	434
5.1. Cyclin-dependent kinases (CDKs)	434
5.2. Polo-like kinases (PLKs)	442
5.3. Checkpoint kinases (CHKs)	443
5.4. PI3K/PDPK1/AKT/mTOR kinases pathway	445
5.4.1. <i>PI3K Inhibitors</i>	445
5.4.2. <i>Phosphatidylinositide-dependent protein kinase 1 (PDPK1) inhibitors</i>	449
5.4.3. <i>AKT inhibitors</i>	449
5.4.4. <i>MTOR inhibitors</i>	451
5.4.5. <i>Inhibitors of SGK1</i>	452
5.5. Aurora kinases	453
5.6. Protein kinase C (PKC) modulators	455
5.7. Inhibitors of Pim kinases	458
6. Inhibitors of the Ras/Raf/MEK signaling pathway	458
6.1. Introduction to Ras signaling	458
6.2. Inhibitors of Ras protein expression	462
6.3. Inhibitors of Ras processing by farnesyltransferase	462
6.3.1. <i>Farnesyl pyrophosphate mimics</i>	465
6.3.2. <i>Peptides and peptidomimetics that mimic the CAAX motif</i>	465
6.3.3. <i>Bisubstrate analogs</i>	469
6.3.4. <i>Inhibitors of farnesyl diphosphate synthase and geranylgeranyl diphosphate synthase</i>	469
6.4. Inhibitors of the attachment of farnesyl–Ras to the cell membrane	470
6.5. Inhibitors of downstream effectors of the Ras function	470
6.5.1. <i>Raf inhibitors</i>	470
6.5.2. <i>MEK inhibitors</i>	474
6.5.3. <i>The MAPK (ERK) pathway</i>	475
6.5.4. <i>Jun kinases and p38 MAPK pathways</i>	476
7. Transforming growth factor-β–smad signaling	478
8. Glucose metabolism and cancer: inhibitors of kinases involved in anaerobic glycolysis	480
References	484

1 INTRODUCTION

Conventional anticancer drugs have been traditionally focused on targeting DNA processing and cell division. They can be very efficacious, but their lack of selectivity for tumor cells usually leads to serious side effects. By the late 1980s, advances in molecular biology begun to provide a greatly increased understanding of regulatory and signaling networks in normal cells that control fundamental cellular processes such as vascularization, growth, and proliferation. All these processes are greatly enhanced in tumor cells in response to different factors through complex mechanisms in which several signaling pathways are responsible for transforming normal cells into malignant cancers.¹